Novel 3-D Printed Implant for Improved Hemodialysis Access

Information

  • Research Project
  • 10081495
  • ApplicationId
    10081495
  • Core Project Number
    R44HL154933
  • Full Project Number
    1R44HL154933-01
  • Serial Number
    154933
  • FOA Number
    PA-19-272
  • Sub Project Id
  • Project Start Date
    7/24/2020 - 4 years ago
  • Project End Date
    6/30/2022 - 2 years ago
  • Program Officer Name
    LEE, ALBERT
  • Budget Start Date
    7/24/2020 - 4 years ago
  • Budget End Date
    6/30/2021 - 3 years ago
  • Fiscal Year
    2020
  • Support Year
    01
  • Suffix
  • Award Notice Date
    7/23/2020 - 4 years ago
Organizations

Novel 3-D Printed Implant for Improved Hemodialysis Access

Project Summary/Abstract The overall goal of this Direct to Phase II SBIR proposal is to develop the Ark, a novel device for providing improved access, protection, and functionality during placement of hemodialysis needles. In the US alone, over 700,000 patients receive hemodialysis treatment, and creation of an arteriovenous fistula (AVF) and access vein is the preferred access point for dialysis needles. Most access veins suffer from the following shortcomings: long waiting periods to mature; challenging to access; prone to damage by needle penetration through the vessel; and limited useful life, failing largely because of both excessive and poor punctures. As a result, many dialysis patients do not receive the treatment required for continued quality of life. The Ark is designed to remediate the limitations of the current practice and aid long-term use of access veins. The Ark is intended for surgical implantation around the access vein, ideally at the time of AVF creation. The infrastructure promotes ingrowth of surrounding soft tissues reinforcing the strength of the vein, while providing an opening for easy needle access and a back wall for vessel protection from inadvertent penetration. The implant provides a palpable structure beneath the skin, promoting more accurate needle puncture, improving both caregiver efficacy and patient comfort. Initial prototypes of the Ark have gone through preliminary benchtop and animal studies demonstrating feasibility and significant promise. Continued efforts will build on these results to optimize the design, perform cannulation studies in a relevant AVF animal model, complete required design controls and validation activities, and perform a chronic GLP study, supporting a planned submission for FDA Clearance. We expect the end result of this effort will greatly facilitate the move toward home-based dialysis, resulting in significant impact on patient health and health care cost savings.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    795029
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:795029\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BIOTEX, INC.
  • Organization Department
  • Organization DUNS
    969792050
  • Organization City
    HOUSTON
  • Organization State
    TX
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    770451507
  • Organization District
    UNITED STATES